Cresemba Dosing and Monitoring
For adult patients, Cresemba (isavuconazonium sulfate) requires a loading dose of 372 mg IV or PO every 8 hours for 6 doses (48 hours), followed by maintenance dosing of 372 mg once daily starting 12-24 hours after the last loading dose. 1
Adult Dosing Regimen
Loading Phase:
- 372 mg (equivalent to 200 mg isavuconazole) every 8 hours for 6 doses over 48 hours
- Can be administered IV or orally (capsules: two 186 mg capsules or five 74.5 mg capsules)
- Oral capsules can be taken with or without food 1
Maintenance Phase:
- 372 mg once daily
- Start 12-24 hours after the last loading dose
- Same formulation options as loading phase 1
IV Administration Requirements:
- Must be administered through an in-line filter
- Infuse over minimum of 1 hour 1
Hepatic Impairment Adjustments
Critical distinction: Cresemba does NOT require dose adjustment for hepatic impairment. This represents a significant advantage over voriconazole, which requires dose reduction in mild-to-moderate hepatic dysfunction 2, 3. The FDA label for Cresemba does not specify hepatic dose adjustments 1, making it a safer choice in patients with liver disease.
Monitoring Parameters
Hepatic Function:
- Evaluate liver-related laboratory tests at baseline and during therapy
- Serious hepatic reactions have been reported, though dose adjustment is not required 1
Infusion-Related Reactions:
- Monitor during IV administration
- Discontinue infusion if reactions occur 1
Drug Interactions:
- Contraindicated with:
- Strong CYP3A4 inhibitors (ketoconazole, high-dose ritonavir)
- Strong CYP3A4 inducers (rifampin, carbamazepine, St. John's wort, long-acting barbiturates)
- Patients with familial short QT syndrome 1
Hypersensitivity:
- Monitor for anaphylactic reactions and serious skin reactions
- Discontinue immediately if these occur 1
Comparison to Voriconazole in Hepatic Impairment
This is where Cresemba demonstrates clear superiority. Voriconazole requires significant dose reductions in hepatic dysfunction:
- Child-Pugh Class A/B: Reduce voriconazole maintenance dose to one-third (e.g., 75 mg q12h or 150 mg q24h) 4, 5, 6
- Child-Pugh Class C: Reduce to one-fourth (e.g., 50 mg q12h or 100 mg q24h) 4, 5, 6
- Loading doses should be halved in cirrhotic patients 4
- Voriconazole clearance drops dramatically: 7.59 L/hour in normal patients to 1.86 L/hour in Child-Pugh A/B and 0.93 L/hour in Child-Pugh C 4
Cresemba requires no such adjustments, making dosing straightforward regardless of hepatic function 1.
Renal Considerations
Cresemba IV formulation: No specific renal dose adjustment mentioned in the label, though the IV formulation should be used cautiously as with all IV azoles 1
Oral formulation: No renal adjustments required 1
This contrasts with voriconazole IV, which is not recommended when creatinine clearance <50 mL/min due to cyclodextrin accumulation concerns 2, 3.
Clinical Advantages
Cresemba offers several practical benefits:
- No therapeutic drug monitoring required (unlike voriconazole which requires TDM to maintain trough 1-5.5 mg/L) 7, 3
- No hepatic dose adjustment needed
- Simpler dosing schedule after loading phase
- Lower potential for drug-drug interactions compared to voriconazole
- Oral bioavailability allows seamless IV-to-PO transition without dose change
Common pitfall: Do not confuse Cresemba with voriconazole—they have completely different dosing requirements and monitoring needs. Cresemba's straightforward dosing without need for dose adjustment or routine TDM makes it operationally simpler in clinical practice.